UNSPSC 51123902: Eproxindine

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E229K2HE7F. European Medicines Agency schedules Eproxindine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06588MIG. Eproxindine generally arises in the molecular formula C23H29N3O3.

UNSPSC 51123902 Eproxindine is a Commodity code covering individual pharmaceutical active ingredients and their formulations supplied to state and local healthcare and emergency response agencies. State and local governments procure under this code to stock emergency medications, maintain pharmacy inventories in correctional facilities and public health departments, and support fire rescue and EMS operations. The issuing bodies span city and county purchasing offices managing emergency services, state health and human services departments overseeing medicaid and employee health programs, and cooperative purchasing alliances aggregating demand across multiple jurisdictions. The scope reflects real-world procurement of specific medication line items—epinephrine, labetalol, adenosine, diltiazem, and comparable formulations—with strict expiration-date and shelf-life requirements, delivery timelines measured in days, and compliance mandates for manufacturing practices and hazard communication.

Recent activity is concentrated in the South and Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, with a response date of April 8, 2026 and an estimated contract value of $40,000; the solicitation required sealed bids for four specific medication line items with a one-year term and renewal options, and included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response date and a two-year term, requiring vendors to work through three authorized wholesalers and meet FDA compliance and cGMP certification. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future procurement volume but representing exploratory activity rather than an immediate buying opportunity.